Genelux Corporation

NASDAQ:GNLX

Biotechnology

Healthcare
$2.24 +2.63%

+$0.08 today

Market cap
$107.66M
Beta
0.55
P/E (TTM)
-3.0
EPS (TTM)
-$0.98
52W Low $2.29High $8.54

Volume 0.80M

Average 0.19M

GNLX Pre-Tax Margin

Income before tax as a percentage of revenue.

Genelux CorporationNASDAQ: GNLX

Pre-Tax Margin · Q1 FY2026 · quarter ended Mar 2026

Pre-tax margin not reported for Q1 FY2026

Over 3 fiscal years it narrowed by 401775.4 pp.

Context

  • Pre-tax margin widened in 0 of the last 3 fiscal years.
  • FY2025 was the lowest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
—— QoQ
Last fiscal yearDec 2025
-401812.5%-28450.0 pp YoY
LTMMar 2026
-397225.0%— YoY
Pre-Tax Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter———
1 year-28450.0 pp——
3 years-401775.4 pp——
5 years——
10 years——

Pre-Tax Margin history

Percent of revenue · from the income statement

Latest · FY2025
-401812.5%
Year-over-year change
-28450.0pp

Pre-Tax Margin vs competitors

How GNLX compares with its peers on the latest reported figures

  • GNLX's LTM Mar 2026 pre-tax margin of -397225.0% is the 5th highest of the 6 companies compared; the peer median is -7158.7%.
  • Over three fiscal years its change of -401775.4 pp compares with a peer median of -7897.3 pp.
GNLX Competitors Peer median
Pre-Tax Margin for GNLX and competitors
Company Period LTM level YoY 3-year change
CLLSCellectis S.A.LTM Mar 2026-102.0% +24.5 pp+421.1 pp
ACIUAC Immune S.A.LTM Mar 2026-1788.8% -1604.8 pp-173.9 pp
MREOMereo BioPharma Group plcLTM Mar 2026-7158.7% ——
SLNSilence Therapeutics plcLTM Mar 2026-9241.5% —-15620.7 pp
GNLXGenelux CorporationLTM Mar 2026-397225.0% —-401775.4 pp
LYELLyell Immunopharma, Inc.LTM Mar 2026-794858.1% -280208.8 pp-762139.3 pp
DRTSAlpha Tau Medical Ltd.FY2025— ——
CADLCandel Therapeutics, Inc.FY2025— ——
CTNMContineum Therapeutics, Inc. Class A Common StockFY2025— ——
LXEOLexeo Therapeutics, Inc. Common StockFY2025— ——
ALDXAldeyra Therapeutics, Inc.FY2025— ——
Peer median (excluding GNLX) -7158.7%-1604.8 pp-7897.3 pp

Competitors are the stored peer set for GNLX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue011.07M170K8K8K
Cost of Revenue895K968K1.02M903K574K
Gross Profit(895K)10.1M(848K)(895K)(566K)
Gross Margin—91.3%-498.8%-11187.5%-7075.0%
Research & Development6.32M9.08M12.77M19M19.85M
Selling, General & Admin8.29M5M11.57M12.71M13.37M
Operating Expenses13.72M13.11M23.32M30.8M32.65M
Depreciation & Amortization895K968K1.02M903K574K
EBITDA(13.67M)(1.73M)(26.46M)(28.97M)(31.57M)
EBITDA Margin—-15.6%-15562.9%-362075.0%-394637.5%
Operating Income(14.61M)(3.01M)(24.17M)(31.7M)(33.21M)
Operating Margin—-27.2%-14214.7%-396200.0%-415175.0%
Interest Income00244K1.46M1.07M
Interest Expense1.82M1.41M3.97M00
Other Income / Expenses(1.77M)(1.09M)(4.13M)1.83M1.07M
Income Before Tax(16.38M)(4.11M)(28.3M)(29.87M)(32.15M)
Pre-Tax Margin—-37.1%-16645.3%-373362.5%-401812.5%
Income Tax Expense01.1M000
Net Income(17.8M)(5.21M)(28.3M)(29.87M)(32.15M)
Net Margin—-47.0%-16645.3%-373362.5%-401812.5%
EPS (Basic)(0.69)(0.21)(1.16)(0.95)(0.86)
EPS (Diluted)(0.69)(0.21)(1.16)(0.95)(0.86)
Weighted Avg Shares23.62M24.55M24.43M31.45M37.18M
Weighted Avg Shares (Diluted)23.62M24.55M24.43M31.45M37.18M

Genelux Corporation

NASDAQ:GNLX

Intrinsic Alpha fair value

Locked

Current Price

$2.24

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.